Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007

Authors


Corresponding author: N. De Castro, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
E-mail: nathalie.de-castro@sls.aphp.fr

Abstract

Clin Microbiol Infect 2012; 18: E185–E187

Abstract

We report a retrospective study of 24 patients with haematological malignancy and hepatosplenic candidiasis. Clinical and biological features were similar to previous reports. No patient previously received antifungal prophylaxis. Liver or spleen histological examination revealed yeasts in 6/24 patients (25%) on direct examination but all cultures were negative. After a median duration of 7 months, antifungal treatment was discontinued in 58% of the patients with no relapse. Eleven (46%) patients died during follow up. After multivariate analysis, independent factors associated with death were the duration of neutropenia (p 0.022) and relapsing haematological malignancy (p 0.015).

Ancillary